Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of a molecular tumour board in LATAM: the impact on treatment decisions for patients evaluated at Instituto Alexander Fleming, Argentina.
Angel MO, Pupareli C, Soule T, Tsou F, Leiva M, Losco F, Esteso F, O Connor JM, Luca R, Petracci F, Girotti R, Mahmoud YD, Martín C, Chacón M. Angel MO, et al. Among authors: pupareli c. Ecancermedicalscience. 2021 Nov 1;15:1312. doi: 10.3332/ecancer.2021.1312. eCollection 2021. Ecancermedicalscience. 2021. PMID: 35047063 Free PMC article.
Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2.
Narváez D, Waisberg F, Soulé T, Angel M, Bruno L, Girotti MR, Pupareli C, Chacón M, Petracci FE. Narváez D, et al. Among authors: pupareli c. Ecancermedicalscience. 2022 Sep 26;16:1448. doi: 10.3332/ecancer.2022.1448. eCollection 2022. Ecancermedicalscience. 2022. PMID: 36405946 Free PMC article.
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report.
Enrico D, Tsou F, Catani G, Pupareli C, Girotti MR, Ulloa Alvarez DE, Waisberg F, Rodríguez A, Reyes R, Chacón M, Reguart N, Martín C. Enrico D, et al. Among authors: pupareli c. JTO Clin Res Rep. 2022 Dec 28;4(2):100456. doi: 10.1016/j.jtocrr.2022.100456. eCollection 2023 Feb. JTO Clin Res Rep. 2022. PMID: 36798785 Free PMC article.
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Juliá EP, et al. Among authors: pupareli c. Cancer Immunol Immunother. 2019 Oct;68(10):1585-1596. doi: 10.1007/s00262-019-02391-z. Epub 2019 Sep 12. Cancer Immunol Immunother. 2019. PMID: 31515670 Free PMC article.
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).
Enrico D, Gomez JE, Aguirre D, Tissera NS, Tsou F, Pupareli C, Tanco DP, Waisberg F, Rodríguez A, Rizzo M, Minatta N, Rafael P, Basbus L, Lupinacci L, Kaen D, Ramos M, Bluthgen V, Castagneris N, Coppola MP, Scocimarro A, Guerra MF, Perfetti A, Levit P, Galvez-Nino M, Mas L, Rojas L, Zuluaga J, Chacón M, Corrales L, Samtani S, Arrieta O, Cardona A, Remon J, Martín C. Enrico D, et al. Among authors: pupareli c. Clin Lung Cancer. 2024 Dec;25(8):723-731.e2. doi: 10.1016/j.cllc.2024.09.005. Epub 2024 Sep 21. Clin Lung Cancer. 2024. PMID: 39424512
Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G, Enrico D, Mahmoud YD, Ruiz A, Cantarella MF, Leguina L, Barberis M, Beña A, Brest E, Starapoli S, Mendoza Bertelli A, Tsou F, Pupareli C, Coppola MP, Scocimarro A, Sena S, Levit P, Perfetti A, Aman E, Girotti MR, Arrieta O, Martín C, Salanova R. Ruiz G, et al. Among authors: pupareli c. Thorac Cancer. 2024 Apr;15(11):895-905. doi: 10.1111/1759-7714.15244. Epub 2024 Mar 8. Thorac Cancer. 2024. PMID: 38456253 Free PMC article.
High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM, Solano AR, Neuman MI, Veschi S, Morgano A, Malatesta S, Chacon RD, Pupareli C, Lombardi M, Battista P, Marchetti A, Mariani-Costantini R, Podestà EJ. Aceto GM, et al. Among authors: pupareli c. Breast Cancer Res Treat. 2010 Aug;122(3):671-83. doi: 10.1007/s10549-009-0596-6. Epub 2009 Oct 23. Breast Cancer Res Treat. 2010. PMID: 19851859